[Treatment of ALK negative metastatic inflammatory myofibroblastic tumor by combination of pembrolizumab and anlotinib: a case report].

Li, X S; Li, X F; Jin, L F; Zhao, Y; Shen, W Z

Li, X S; Li, X F; Jin, L F; Zhao, Y; Shen, W Z.

Afiliación

Li XS; Department of Oncology and Hematology, the Second Hospital of Jilin University, Changchun 130041, China.
Li XF; Department of Oncology and Hematology, the Second Hospital of Jilin University, Changchun 130041, China.
Jin LF; Department of Oncology and Hematology, the Second Hospital of Jilin University, Changchun 130041, China.
Zhao Y; Department of Oncology and Hematology, the Second Hospital of Jilin University, Changchun 130041, China.
Shen WZ; Department of Oncology and Hematology, the Second Hospital of Jilin University, Changchun 130041, China.

Zhonghua Zhong Liu Za Zhi ; 43(2): 240-242, 2021 02 23.

Article en Zh | MEDLINE | ID: mdl-33601493

Asunto(s)

Neoplasias; Quinolinas; Anticuerpos Monoclonales Humanizados; Biomarcadores de Tumor; Humanos; Indoles; Proteínas Tirosina Quinasas Receptoras

Palabras clave

Antiangiogenics; Immune checkpoint; Inflammatory myofibroblastic tumors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolinas / Neoplasias Límite: Humans Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google